First-line Abraxane/Xeloda Doublet Viable in Metastatic Breast Cancer

March 1, 2007

In a phase II,multicenter open-label study, Lee S.Schwartzberg, MD, et al evaluated 50patients with metastatic breast cancertreated with nab-paclitaxel (Abraxane)at 125 mg/m2 on days 1 and 8 andcapecitabine (Xeloda) at 825 mg/m2 bidon days 1–14 of a q3wk cycle (abstract1096).

MEMPHIS–In a phase II,multicenter open-label study, Lee S.Schwartzberg, MD, et al evaluated 50patients with metastatic breast cancertreated with nab-paclitaxel (Abraxane)at 125 mg/m2 on days 1 and 8 andcapecitabine (Xeloda) at 825 mg/m2 bidon days 1-14 of a q3wk cycle (abstract1096). The protocol was designed for 6cycles of therapy; some patients receivedup to 14 cycles (36 weeks). Data wereavailable on 38 patients at interim analysis.ORR was 53% (9% CR, 44% PR),and the 50% survival endpoint has notbeen reached. The only grade 4 toxicitywas hematologic (3 patients). Investigatorsnoted a 10% incidence each of neuropathyand hand-foot syndrome.